372 related articles for article (PubMed ID: 25400118)
1. Regulation of ERBB3/HER3 signaling in cancer.
Mujoo K; Choi BK; Huang Z; Zhang N; An Z
Oncotarget; 2014 Nov; 5(21):10222-36. PubMed ID: 25400118
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic ERBB3 mutations in human cancers.
Jaiswal BS; Kljavin NM; Stawiski EW; Chan E; Parikh C; Durinck S; Chaudhuri S; Pujara K; Guillory J; Edgar KA; Janakiraman V; Scholz RP; Bowman KK; Lorenzo M; Li H; Wu J; Yuan W; Peters BA; Kan Z; Stinson J; Mak M; Modrusan Z; Eigenbrot C; Firestein R; Stern HM; Rajalingam K; Schaefer G; Merchant MA; Sliwkowski MX; de Sauvage FJ; Seshagiri S
Cancer Cell; 2013 May; 23(5):603-17. PubMed ID: 23680147
[TBL] [Abstract][Full Text] [Related]
3. Targeting of erbB3 receptor to overcome resistance in cancer treatment.
Ma J; Lyu H; Huang J; Liu B
Mol Cancer; 2014 May; 13():105. PubMed ID: 24886126
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
[TBL] [Abstract][Full Text] [Related]
5. HER3/ErbB3, an emerging cancer therapeutic target.
Zhang N; Chang Y; Rios A; An Z
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):39-48. PubMed ID: 26496898
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathways: HER3 targeted therapy.
Gala K; Chandarlapaty S
Clin Cancer Res; 2014 Mar; 20(6):1410-6. PubMed ID: 24520092
[TBL] [Abstract][Full Text] [Related]
7. The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling.
Huang Z; Choi BK; Mujoo K; Fan X; Fa M; Mukherjee S; Owiti N; Zhang N; An Z
Oncogene; 2015 Feb; 34(9):1105-15. PubMed ID: 24662824
[TBL] [Abstract][Full Text] [Related]
8. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.
Kiavue N; Cabel L; Melaabi S; Bataillon G; Callens C; Lerebours F; Pierga JY; Bidard FC
Oncogene; 2020 Jan; 39(3):487-502. PubMed ID: 31519989
[TBL] [Abstract][Full Text] [Related]
9. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.
Verlingue L; Hollebecque A; Lacroix L; Postel-Vinay S; Varga A; El Dakdouki Y; Baldini C; Balheda R; Gazzah A; Michot JM; Marabelle A; Mir O; Arnedos M; Rouleau E; Solary E; De Baere T; Angevin E; Armand JP; Michiels S; André F; Deutsch E; Scoazec JY; Soria JC; Massard C
Eur J Cancer; 2018 Mar; 92():1-10. PubMed ID: 29413684
[TBL] [Abstract][Full Text] [Related]
10. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
11. The role of HER3 in gastric cancer.
Wang L; Yuan H; Li Y; Han Y
Biomed Pharmacother; 2014 Jul; 68(6):809-12. PubMed ID: 25194439
[TBL] [Abstract][Full Text] [Related]
12. Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.
Verma N; Müller AK; Kothari C; Panayotopoulou E; Kedan A; Selitrennik M; Mills GB; Nguyen LK; Shin S; Karn T; Holtrich U; Lev S
Cancer Res; 2017 Jan; 77(1):86-99. PubMed ID: 27793840
[TBL] [Abstract][Full Text] [Related]
13. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract][Full Text] [Related]
14. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
17. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.
Stern DF
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):215-23. PubMed ID: 18454306
[TBL] [Abstract][Full Text] [Related]
18. SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells.
Jenke R; Holzhäuser-Rein M; Mueller-Wilke S; Lordick F; Aigner A; Büch T
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374770
[TBL] [Abstract][Full Text] [Related]
19. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
20. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
